These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1283501)

  • 1. Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray.
    Shimazaki J; Higa T; Akimoto S; Masai M; Isaka S
    Adv Exp Med Biol; 1992; 324():269-75. PubMed ID: 1283501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical course of bone metastases by prostatic cancer studies with conventional X-ray].
    Higa T; Akimoto S; Isaka S; Shimazaki J; Goto S
    Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):734-43. PubMed ID: 1875568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 6. Objective treatment response to endocrine therapy in metastatic prostate cancer.
    Zaragoza MR; Grossman HB
    Urology; 1992 Nov; 40(5):405-8. PubMed ID: 1441036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
    Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Factors influencing prognosis of stage D2 prostatic cancer following endocrine therapy: comparison between short-term cancer death and long-term survival group].
    Masai M; Akimoto S; Isaka S; Shimazaki J; Yatani R
    Hinyokika Kiyo; 1990 Jun; 36(6):667-71. PubMed ID: 1700585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
    Akaza H; Usami M; Kotake T; Koiso K; Aso Y
    Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
    Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
    J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
    Otsuka S; Hanibuchi M; Ikuta K; Yano S; Goto H; Ogino H; Yamada T; Kakiuchi S; Nishioka Y; Takahashi T; Sone S
    Oncol Res; 2009; 17(11-12):581-91. PubMed ID: 19806789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of prostate cancer associated with osteolytic bone metastases].
    Migita T; Maeda K; Ogata N
    Hinyokika Kiyo; 1999 May; 45(5):371-4. PubMed ID: 10410324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endocrine therapy of stage D2 prostate cancer--comparison of drugs used for total androgen blockade].
    Tanaka M; Murakami S; Suzuki N; Hamano S; Kinsui H; Oikawa T; Shimazaki J
    Hinyokika Kiyo; 2000 Jan; 46(1):9-14. PubMed ID: 10723657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
    Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CT findings of bone metastasis].
    Nosaki T; Murai T; Okumura A; Furuki T; Mori K; Tsuji S; Nakanishi K; Kobayashi M; Fukui A; Fujii K
    Rinsho Hoshasen; 1989 Sep; 34(9):991-7. PubMed ID: 2810844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M; Serretta V; Daricello G; Pavone C; Cacciatore M; Romano C; Cavallo N
    Prog Clin Biol Res; 1990; 350():149-57. PubMed ID: 2201041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed tomographic evaluation of bone metastases in prostatic cancer patients.
    Yoshida K; Akimoto M
    Adv Exp Med Biol; 1992; 324():197-204. PubMed ID: 1283499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysis of osteoblastic lesions in prostatic cancer: a sign of progression.
    Pollen JJ; Reznek RH; Talner LB
    AJR Am J Roentgenol; 1984 Jun; 142(6):1175-9. PubMed ID: 6609604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum?
    Ortiz A; Lin SH
    Recent Results Cancer Res; 2012; 192():225-33. PubMed ID: 22307378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.